Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.
about
Imaging metabolic heterogeneity in cancerMolecular and functional imaging technology for the development of efficient treatment strategies for gliomas.Post-treatment imaging changes in primary brain tumors.Imaging biomarkers in primary brain tumours.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Imaging in neurooncologyDetecting tumor progression in glioma: Current standards and new techniques.The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood.[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors.3'-Deoxy-3'-[(18)F]fluorothymidine and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative StudyAnaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromesTreatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapyImaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice.Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.PET Imaging in Patients with Meningioma - Report of the RANO/PET Group.Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative AssessmentSerial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant gliomaMolecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.Simultaneous 11C-Methionine Positron Emission Tomography/Magnetic Resonance Imaging of Suspected Primary Brain Tumors.Positron emission tomography: clinical applications in oncology. Part 2.Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomographyTryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI.Evaluation of the biodistribution of 11C-methionine in children and young adults.An automated voxel-based method for calculating the reference value for a brain tumour metabolic index using 18F-FDG-PET and 11C-methionine PET.Imaging with non-FDG PET tracers: outlook for current clinical applications.Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategiesResponse Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.A comparison study of (11)C-methionine and (18)F-fluorodeoxyglucose positron emission tomography-computed tomography scans in evaluation of patients with recurrent brain tumors.Comparision of F-18 FDG and C-11 Methionine PET/CT for demonstration of subependymal deposit in a treated case of glioblastoma multiforme[ (11) C]-methionine positron emission tomography in the postoperative imaging and followup of patients with primary and recurrent gliomas.Rapid and efficient synthesis of [11C]ureas via the incorporation of [11C]CO2 into aliphatic and aromatic amines.18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence.Visual and semiquantitative 11C-methionine PET: An independent prognostic factor for survival of newly diagnosed and treatment naive gliomas.Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences.Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients.How treatment monitoring is influencing treatment decisions in glioblastomas.Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.
P2860
Q28076500-D64E58E2-1DED-4844-B158-C9916488A118Q30775012-D134A69F-F8B5-4B85-8652-4579672FED36Q30835236-BDE182E4-BEB2-4347-9013-20EE34168234Q30880129-6F9E14B5-9712-4754-80E7-D218C2479CA5Q30907831-ACC57CB2-B005-4967-A0D7-75CC934D1790Q30989939-B9D4FA34-E8D5-4076-9589-38387CF9C840Q31132701-05D781F2-7F29-467D-9FD4-63E1F90625F5Q33464358-5C36FEC7-C87A-4AF3-955F-79191DF0BE66Q33599162-DF0CBDD8-FAF3-4350-AC0C-80CE1B9CB84CQ33704202-15E68C01-D5D6-416D-A5E4-81C51889D26DQ33814485-1969A4BD-DBDA-4535-AFB4-21ED15DFE867Q33838502-A5443BC4-5082-44BF-97A4-EF34BFA02948Q33862844-18562640-EA50-45ED-BDB0-7195DE266633Q34348544-DE54D18B-352B-4F8B-B3D5-38775F102246Q34404416-1D5361C2-48B0-4C0F-913F-6E220CC6B809Q34682187-B028B273-B763-483B-AC1E-E4FA36F8849CQ35689330-99D53191-427A-43EB-B1D4-8BBEB21395AAQ36021392-38D60E7C-B639-4CCA-9045-A26B7F311C13Q36107379-BBC194E6-5D72-4609-A094-6B50546A69D3Q36210293-4704D948-6D3A-4F3A-86E6-DF1EF7EF801EQ36448703-C29DC301-CB31-4E71-B910-6112AA6E88FDQ36474762-079D7071-4CF8-4640-81CC-0B408424C3FCQ37235829-C409A8DA-0094-4B19-B50E-802F9EC80025Q37432387-ABF6EAC4-1CE4-4ECD-B554-8DDB9B15FE16Q37584750-64592797-3A02-4631-9F22-F1F8A8001E94Q37703206-B31482E3-4520-402A-8F52-C36EF125614BQ37986065-BBC17EB7-D8D8-49D7-BA27-09FFCD7239E3Q38074638-C0A97430-42F6-48F6-AEF4-7DCD5E5FE20EQ38815396-1E9EBAD1-1FD7-4881-BE48-44054EC0F456Q39724277-8580170F-9CA2-4A77-9E64-6A7B56160530Q39771049-3467775B-988F-4298-B37A-79C0B3578C70Q41871381-A209D8EB-A43D-41DF-9BC4-AAAA425EF355Q43776076-43291AB2-D899-44E6-B7A0-FF3C93EE5662Q46366163-540CBB7C-D890-4ECE-829A-C3AFA591DA07Q47114149-8621E436-39C8-4756-AE02-DD83D34800E0Q47583631-0D3D4304-78A0-4B10-A732-89BBA8A747F2Q48158155-EB4DEBBF-8D15-479E-BFF0-F3E4F670D8C0Q48241629-AD84C89F-FC7F-462E-970F-C7EC1060CEC6Q48292017-A5595AEF-7AF3-4E10-8AF6-C1A1440B4F04Q48346347-30D0E117-CCD7-4538-AF23-BF1741FEBEF6
P2860
Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Usefulness of 11C-methionine P ...... r isometabolic on 18F-FDG PET.
@en
Usefulness of 11C-methionine P ...... r isometabolic on 18F-FDG PET.
@nl
type
label
Usefulness of 11C-methionine P ...... r isometabolic on 18F-FDG PET.
@en
Usefulness of 11C-methionine P ...... r isometabolic on 18F-FDG PET.
@nl
prefLabel
Usefulness of 11C-methionine P ...... r isometabolic on 18F-FDG PET.
@en
Usefulness of 11C-methionine P ...... r isometabolic on 18F-FDG PET.
@nl
P2093
P1476
Usefulness of 11C-methionine P ...... r isometabolic on 18F-FDG PET.
@en
P2093
Dong Soo Lee
Hee Won Jung
Jae Min Jeong
Jeong Seok Yeo
June-Key Chung
Myung Chul Lee
Seok-ki Kim
Suntta Paek
Yong Jin Lee
Yu Kyeong Kim
P2888
P304
P356
10.1007/S00259-001-0690-4
P577
2002-02-01T00:00:00Z